Please See Important Safety Information, Including Boxed Warning Below

Equetro® (carbamazepine) Extended-Release Capsules Patient and Family Information Pack

To help Patients and Caregivers to learn more about Bipolar I Disorder and gain the greatest benefit from Equetro® (carbamazepine) Extended-Release Capsules therapy, Validus Pharmaceuticals is pleased to provide three helpful downloadable tools.

Read the simple directions below to download the tools and put them to use.

Equetro® Patient and Family Guide

Written in non-technical language, this booklet describes Bipolar I Disorder and explains how treatment with Equetro® helps alleviate its symptoms.2 Also included is helpful guidance on living successfully with Bipolar I Disorder.

Equetro® Mood Diary

This handy chart helps people with Bipolar I Disorder track their symptoms and mood swings so they can discuss their condition with their doctor and map the progress of their recovery. Spaces are provided to record medications, sleep patterns, and daily observations.

Questions to Discuss with your Doctor

This tool lists simple questions that help people with Bipolar I Disorder to remember the important questions and issues they'd like to discuss with their healthcare providers at a future appointment.

In order to view PDF Documents, you must have Adobe® Reader® installed on your computer. If you do not have it, you may download it for free at the Adobe Web Site.

WARNING

Important Safety Information about Equetro® (carbamazepine) Extended-Release Capsules

Warning Serious Dermatologic Reactions and HLA-B*1502 Allele

Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported during treatment with carbamazepine. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly caucasian populations, but the risk in some Asian countries is estimated to be about 10 times higher. Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. HLA-B*1502 is found almost exclusively in patients with ancestry across broad areas of Asia. Patients with ancestry in genetically at-risk populations should be screened for the presence of HLA-B*1502 prior to initiating treatment with Equetro® (carbamazepine) Extended-Release Capsules. Patients testing positive for the allele should not be treated with Equetro® (carbamazepine) Extended-Release Capsules unless the benefit clearly outweighs the risk (see warnings and precautions, laboratory tests).

Aplastic Anemia and Agranulocytosis

Aplastic Anemia and Agranulocytosis have been reported in association with the use of carbamazepine. Data from a population based case-control study demonstrate that the risk of developing these reactions is 5–8 times greater than in the general population. However, the overall risk of these reactions in the untreated general population is low, approximately six patients per one million population per year for Agranulocytosis and two patients per one million population per year for Aplastic Anemia.

Although reports of transient or persistent decreased platelet or white blood cell counts are not uncommon in association with the use of carbamazepine, data are not available to estimate accurately their incidence or outcome. However, the vast majority of the cases of leukopenia have not progressed to the more serious conditions of Aplastic Anemia or Agranulocytosis.

Because of the very low incidence of Agranulocytosis and Aplastic Anemia, the vast majority of minor hematologic changes observed in monitoring of patients on carbamazepine are unlikely to signal the occurrence of either abnormality. Nonetheless, complete pretreatment hematological testing should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered if any evidence of significant bone marrow depression develops.

Anti-epileptic drugs (AEDs), including Equetro®, may increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence of worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Please see FULL PRESCRIBING INFORMATION including contraindications, warnings and precautions, and boxed warning for additional safety information on Equetro® (carbamazepine) Extended-Release Capsules.

Please see Medication Guide for additional information.